In subjects with different characteristics, different re -weights were observed, the scientists said. | Photo Credit: Getty Images/Istockphoto
The review of data from clinical study studies for weight loss concluded that the re -weight began about eight weeks after stopping these drugs and continues for up to 20 weeks to stabilize for about 26 weeks.
Paper “Body weight trajectory after drug discontinuation in the treatment of medicines against machining“Published in BMC Medicine, open access, transparent -reviewed general medical journal, also noted that after 52 weeks the experiments still weighed less than before the drug, but weight loss decreased compared to drugs.
Scientists, Han Wu et al. These drugs included: GLP-1 receptor agonists (such as semaglutide, liraglutide), Orlistat, Naltrexon-Bupropion and Phentermin-Topiramate. Randomized controlled study studies against machining in the population for at least four weeks followed, followed by four or more weeks after the end of the end.
The review tried to explore the period after the test when the drugs stop, estimate what happens to the weight of these patients, how much weight is regained, how soon they will start to regain the weight and impact of lifestyle factors on weight.
What did the study find out
Scientists noted that people who lost more weight during treatment more often gained weight, although they continued to intervene in lifestyle (including diet and exercise). Those who started with an index of body weight (BMI), which means they were less overweight, showed more weight after stopping than those with higher BMI. Interestingly, people taking drugs related to GLP-1 have experienced more weight after stopping than those on other drugs, they said in the article.
Scientists have stated that for further investigation of potential factors associated with weight change after treatment of treatment, another re -re -re -recurring regain with different characteristics was observed.
“This is an interesting study with robust meta analyzes, but similar results have been demonstrated in many other studies,” says Dr. Nanditha, consultant of diabetology, diabetes of the hospital Dr. A. Ramacandrana, Chennai. “Any intervention, whether when leaving or interruption, will result in weight gain, even if it is a lifestyle adjustment.”
The usefulness of drugs
However, it is important to see the usefulness of these drugs in the context of obesity epidemic. Obesity was originally considered a risk factor, but is now considered a disease in itself. “We haven’t had many treatment tools before; these drugs now provide hope for people who can lose weight without surgery. It is clear that it does not lead you back to the basic weight, so even if these drugs are considered investments because the benefits exceed weight loss,” she said.
It should be remembered that another study that has recently been published in Obesity magazine has shown that Semaglutide and Tirzepatid-Integration drugs GLP-1 for obesity sell lower weight loss compared to clinical evaluation because patients interrupt treatment or use lower maintenance doses.
Published – July 22, 2025 22:39
